Another milestone not only for solid tumors and #allogeneic #NK #celltherapy, but also for cryopreserved starting material! The #cryopreservation process allows to maintain significant cellular cytotoxicity, and potentially making hundreds of thousands of #NKcell doses from a single donor. Learn how CPC Services can help your #clinicaltrial patient sample processing and cryopreservation and storage of starting material. www.cpcservices.com https://lnkd.in/eSPurzXs #immunotherapy #cancerresearch #clinicalresearch
CPC Services ’s Post
More Relevant Posts
-
We need to further define the terms 'organoids' and 'spheroid' cells. Personally, I disagree with labeling patient-derived cells as 'organoids,' as discussed in this paper. However, this patient-derived cell screening approach could provide a valuable opportunity to discover novel therapeutic options, despite some limitations in immuno-oncology. https://lnkd.in/geVM3pKm
A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids - npj Precision Oncology
nature.com
To view or add a comment, sign in
-
Associate Dean for Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial https://lnkd.in/ep2CdfjZ
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial | Journal of Clinical Oncology
ascopubs.org
To view or add a comment, sign in
-
We are excited to announce initial Phase I data of JBI-802 a CoREST inhibitor, which shows therapeutic potential in immunotherapy resistant NSCLC patients with poor prognosis based on their genetic and metastatic pattern. In addition, the on-target dose/exposure-proportional decrease in platelet constitute a proof-of-principle that JBI-802 can be an active compound in hematological malignancies like Essential Thrombocythemia (ET) and other MPN/ MDS characterized by thrombocytosis. A follow up Phase I/II study in MPN/ET and MPN/MDS with thrombocytosis is being planned in first quarter of this year to investigate JBI-802 as potential novel treatment option. Read More: https://lnkd.in/gURiXNPq #nsclc #lungcancer #thrombocythemia #mpn #mds #lsd1 #corest
JBI-802 initial Phase I data suggests therapeutic potential in sensitizing immunotherapy resistant tumors and in Myeloproliferative Neoplasms with thrombocytosis
prnewswire.com
To view or add a comment, sign in
-
Remember the catchphrase from the #Ginsu knives commercial from the ‘80s: “But wait! There’s more!”? The pharmaceutical equivalent of Ginsu knives is the EpicentRx lead therapy, RRx-001 (nibrozetone), which is potentially active in a whole host of indications from cancer to endometriosis, oral mucositis, myocardial infarction, stroke, pulmonary hypertension, and neurodegenerative diseases. But wait! There’s more - so much more to read in this blog post here: https://bit.ly/45yklCS.
But Wait, There’s More! - EpicentRx
https://www.epicentrx.com
To view or add a comment, sign in
-
Professor (assistance)/ Biochemist/ Research Director at islamic Azad University Mashhad Branch Mashhad, Iran
💎💎💎Whatsapp!! 💎💎💎CD5 deletion enhances the antitumor activity of adoptive T cell therapies. The currently available #chimeric #antigen #receptor ( #CAR) #T #cell #therapies have had limited efficacy for a wide range of #solid #cancers and #hematological #malignancies, due in part to CAR T cell #dysfunction. The #scavenger #receptor CD5 is associated with the T cell receptor ( #TCR) and inhibits T cell function. Patel et al. show that #genetic_deletion of #CD5 in #CAR and #TCR T cells enhances expansion, persistence, and #cytotoxicity and is #effective in preclinical solid tumor and hematological malignancy models. These results suggest that CD5 may be a critical negative regulator of CAR T cells that can be therapeutically targeted. ➡ 💎 You can find more pieces of work by clicking here. https://lnkd.in/eSG67K5G https://lnkd.in/dB3s88ei #chimeric #antigen #receptor #CAR #T #cell #therapies
CD5 deletion enhances the antitumor activity of adoptive T cell therapies
science.org
To view or add a comment, sign in
-
For July's #DDU journal club we're highlighting a recent #jmedchem drug annotation describing the development and optimisation of the clinical candidate Sonrotoclax for B-cell malignancies. Sonrotoclax is a protein-protein inhibitor of Bcl-2, a key mediator of cellular apoptosis. It prevents Bcl-2 from sequestering proapoptotic proteins, promoting apoptosis of cancerous cells. The authors used co-crystal structures to design molecules with a novel binding mode in the P2 pocket, distinct to previously disclosed inhibitors, including the clinical approved Bcl-2 inhibitor Venetoclax. An elegant optimisation campaign lead to Sonrotoclax which is undergoing evaluation in Phase II/III clinical trials in several hematologic cancers. https://lnkd.in/eGDkW_Fj
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
pubs.acs.org
To view or add a comment, sign in
-
Tumor infiltrating lymphocytes: complex science, but maybe even more complex launch. At 515K$ per treatment, Iovance will face challenges. TIL therapy originated from research at the National Institutes of Health in the 1980s. It took decades to fine-tune, and Iovance had to overcome multiple regulatory delays bringing the therapy, formerly known as lifileucel, to market. Its clearance is the “culmination of scientific and clinical research efforts,” https://lnkd.in/ebbBwVr3
Iovance, with approval of ‘TIL’ cell therapy, readies for complex launch
biopharmadive.com
To view or add a comment, sign in
-
After NETTER-1, now NETTER-2 reports good news!! Radioligand therapies have certainly revolutionized NET therapeutics and are on cusp of advancing treatment landscape for various solid tumors. We are currently enrolling in trials testing Lu-177-DOTATATE plus novel radiosenitizers like Peposertib (DNA PKi) and Triapine (RNRi) to push the limits further… #theranostics https://lnkd.in/emyESQ28
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
novartis.com
To view or add a comment, sign in
-
Director of Clinical Research Operations @ the University of Pennsylvania- Abramson Cancer Center Clinical Research Unit
Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma At the 2024 ASCO Annual Meeting, Alfred L. Garfall, MD, an associate professor of Hematology-Oncology and section chief for Myeloma | Penn Medicine| discussed new research showing the bispecific monoclonal antibody teclistamab continued to demonstrate durable responses in patients with relapsed/refractory multiple myeloma. https://lnkd.in/e-uP4Nuj
Long-Term Data Support Teclistamab in Relapsed, Refractory Myeloma
oncnursingnews.com
To view or add a comment, sign in